Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor.
We describe the characteristics of SR 48692, a selective, nonpeptide antagonist of the neurotensin receptor. In vitro, this compound competitively inhibits 125I-labeled neurotensin binding to the high-affinity binding site present in brain tissue from various species with IC50 values of 0.99 +/- 0.14 nM (guinea pig), 4.0 +/- 0.4 nM (rat mesencephalic cells), 7.6 +/- 0.6 nM (COS-7 cells transfected with the cloned high-affinity rat brain receptor), 13.7 +/- 0.3 nM (newborn mouse brain), 17.8 +/- 0.9 nM (newborn human brain), 8.7 +/- 0.7 nM (adult human brain), and 30.3 +/- 1.5 nM (HT-29 cells). It also displaces 125I-labeled neurotensin from the low-affinity levocabastine-sensitive binding sites but at higher concentrations (34.8 +/- 8.3 nM for adult mouse brain and 82.0 +/- 7.4 nM for adult rat brain). In guinea pig striatal slices, SR 48692 blocks K(+)-evoked release of [3H]dopamine stimulated by neurotensin with a potency (IC50 = 0.46 +/- 0.02 nM) that correlates with its binding affinity. In a cell line derived from a human colon carcinoma (HT-29), SR 48692 competitively antagonizes neurotensin-induced intracellular Ca2+ mobilization with a pA2 (-log Kapp) values of 8.13 +/- 0.03, which is consistent with results obtained in binding studies. Moreover, SR 48692 is devoid of any intrinsic agonist activity. This compound is also active in vivo, since it reverses at low dose (80 micrograms/kg) the turning behavior induced by intrastriatal injection of neurotensin in mice with similar potency whatever the route of administration (i.p. or orally) and with a long duration of action (6 hr). Thus, being a potent and selective neurotensin receptor antagonist, SR 48692 may be considered as a powerful tool for investigating the role of neurotensin in physiological and pathological processes.
Sanofi Recherche, Toulouse, France.
D
D
Gully
M
M
Canton
R
R
Boigegrain
F
F
Jeanjean
J C
JC
Molimard
M
M
Poncelet
C
C
Gueudet
M
M
Heaulme
R
R
Leyris
A
A
Brouard
D000375:Aging / Q000378:metabolism; D000818:Animals; D000831:Animals, Newborn; D001345:Autoradiography; D001667:Binding, Competitive; D001921:Brain / Q000254:growth & development / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism; D002460:Cell Line; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D007231:Infant, Newborn; D007457:Iodine Radioisotopes; D007700:Kinetics; D008636:Mesencephalon / Q000378:metabolism; D051379:Mice; D009496:Neurotensin / Q000378:metabolism* / Q000494:pharmacology*; D011188:Potassium / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology*; D011804:Quinolines / Q000494:pharmacology*; D051381:Rats; D018028:Receptors, Neurotensin; D017981:Receptors, Neurotransmitter / Q000037:antagonists & inhibitors*; D014162:Transfection
D007457:Iodine Radioisotopes; D011720:Pyrazoles; D011804:Quinolines; D018028:Receptors, Neurotensin; D017981:Receptors, Neurotransmitter; C079087:SR 48692; D009496:Neurotensin; D011188:Potassium; D002118:Calcium; D004298:Dopamine